B-Raf and the inhibitors: from bench to bedside - Wikidata - wikimedia - TriplyDB

B-Raf and the inhibitors: from bench to bedside

B-Raf and the inhibitors: from bench to bedside

http://www.wikidata.org/entity/Q21198860

about

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling.Anti-inflammatory effects of dabrafenib in vitro and in vivo.Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4A Hairy cell leukemia in kidney transplantation: lesson from a rare disorder.Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.Tyrosine kinase gene rearrangements in epithelial malignancies.An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST).Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.Ibrutinib and novel BTK inhibitors in clinical development.Neoadjuvant treatment of melanoma: case reports and review.New RAF kinase inhibitors in cancer therapy.Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.Vemurafenib for the treatment of BRAF mutant metastatic melanoma.The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy.AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.Expression of Death Receptor 4 Is Positively Regulated by MEK/ERK/AP-1 Signaling and Suppressed upon MEK Inhibition.Preclinical analysis of the anti-tumor and anti-metastatic effects of Raf265 on colon cancer cells and CD26(+) cancer stem cells in colorectal carcinoma.Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing.The plasma membrane Ca2+ pump PMCA4b inhibits the migratory and metastatic activity of BRAF mutant melanoma cells.Unlocking the Potential of High-Throughput Drug Combination Assays Using Acoustic Dispensing.Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report.Novel mechanisms of resistance to vemurafenib in melanoma - V600E B-Raf reversion and switching VEGF-A splice isoform expression.Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?Histologic and immunohistochemical predictors of clinical behavior for feline diffuse iris melanoma.Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients.Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy.HS-1371, a novel kinase inhibitor of RIP3-mediated necroptosis Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer

P2860

Q26785828-0BAF1EE1-7153-4CAA-BE9F-7D8C2F315CBC Q28548302-81176BBA-DB86-4464-AC9C-5FBB59A32C9D Q28833514-60331C44-6150-4289-8585-3CDEB1D5833B Q33884726-556ACB07-AA4E-4577-9B36-02C8B3560F7F Q35474544-B3A976AF-783F-4733-93F7-0B3A0997EF6A Q36273868-39CE7ECB-C3EC-444C-96FF-2F1868D9B7FF Q36416861-97C835CD-52E2-4ADB-ACC3-AA5D09C27B2D Q37113464-3523BE2A-DA34-4B78-B3D6-E0A63FD36D09 Q37350230-4862C50A-41E9-41C8-A569-4D3F8A80AAE6 Q37515966-9E33FE0A-295E-4EA9-96E1-309DFBDDDD8F Q38119931-F617710B-2ACC-4517-B81C-8A80798065C1 Q38124821-C69001D1-BAB3-4336-83A7-735163F4A351 Q38130010-8B6F15AE-7B40-4CB4-B07D-C81427775373 Q38185477-D5BF9837-4E6E-4535-91D4-8D2CC6D750B6 Q38207082-A90193C5-4F5B-46DA-9D5B-457B4612BFD2 Q38260357-B546E4A2-DB80-463B-89A6-09ED9705F3F6 Q38357122-56F847F0-2F10-479B-97EF-78DD1E350983 Q38397326-1A1CAF6A-DF13-453C-8DF7-D68DCCA00F00 Q38558611-2F5F4E2E-597F-41B3-A5F9-3F9BA1FAF767 Q38559739-E3647BD5-3761-498B-B359-E5739D68533B Q38578960-3A9BE5FB-7272-479F-8544-FA756435469F Q38585847-5B199CED-BCB3-4CFA-8709-748B24C1102F Q38640917-C7EA5348-2318-40D1-BCC3-6ACA3803306F Q38748966-116BCBEA-4506-486E-885B-41EFEE5E8B3B Q38885822-72C6672A-CCBD-449A-81E7-B58DD949B75F Q38888163-0945AE47-E2CF-4F80-B065-6B7A0697D639 Q39215892-DCF1096C-F0F6-44EF-8B26-B4A77A777C9A Q40752102-D158E2A8-F884-43AA-A5E5-31AC1CDD6491 Q41852171-0CF2ECF3-0D48-4D5B-8B5E-F10CB34BF023 Q42222152-338AA3BA-892E-4335-AC92-27257707EBC1 Q42613711-D900AF96-BCA8-46E5-9CBD-5F0E3023CF1C Q45930485-40E162EB-C7DD-4B60-A463-5EAE39B86C04 Q54325214-730D550B-ED42-40F9-AA83-3915A0316454 Q55279256-DBD5F170-CC6E-4723-B685-74B156289E06 Q58712149-DB471B02-B4AE-46B8-959C-06063DE083A9 Q58769992-F344E265-A54B-4E2C-9CCC-31B7968828E7 Q58806326-2A99A741-3A8E-4BD1-9C5A-3153A3D29C7A

P2860

B-Raf and the inhibitors: from bench to bedside

http://www.wikidata.org/entity/Q21198860

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

B-Raf and the inhibitors: from bench to bedside

@ast

B-Raf and the inhibitors: from bench to bedside

@en

B-Raf and the inhibitors: from bench to bedside

@en-gb

B-Raf and the inhibitors: from bench to bedside

@nl

type

label

B-Raf and the inhibitors: from bench to bedside

@ast

B-Raf and the inhibitors: from bench to bedside

@en

B-Raf and the inhibitors: from bench to bedside

@en-gb

B-Raf and the inhibitors: from bench to bedside

@nl

prefLabel

B-Raf and the inhibitors: from bench to bedside

@ast

B-Raf and the inhibitors: from bench to bedside

@en

B-Raf and the inhibitors: from bench to bedside

@en-gb

B-Raf and the inhibitors: from bench to bedside

@nl

P1433

Q21198860-7CD6B577-ACEE-40B8-B973-FE3F44F5CA6B

P1476

Q21198860-8263C77F-5E5A-46CF-8E77-938DB07D0242

P2093

Q21198860-0DB0BDB5-1AA6-4D2C-9E1D-38602F88B195

Q21198860-7D810046-7947-460F-A0E8-4754DB28FE0A

Q21198860-A3CC8733-25D0-48AA-975E-A59902559BBB

Q21198860-D4DCE64D-B3B2-49A6-B578-A3052319DBA3

Q21198860-DEF80AE5-A312-4ABF-836B-88144205EB25

P275

Q21198860-508A2AC0-A447-4DD4-964F-B3A3C2288DD7

P2860

Q21198860-0265941E-9D43-49F2-874B-225EFF6842DB

Q21198860-08154A0C-82F3-4DCA-9729-6907B5F7D909

Q21198860-0B77011D-2532-474C-AE0D-C3AC38358F86

Q21198860-11584BBE-ACCD-40A0-8F35-2F3BF370F6C1

Q21198860-1932AA2A-3058-485F-809B-DA7532CBA865

Q21198860-1BAD43EF-EDAF-42B2-80A9-732EEE96EDD4

Q21198860-1C94D477-8A7C-42CC-B52B-9976DF24EE6C

Q21198860-1D945695-3674-4E7A-88DA-E3D10309B865

Q21198860-20CB0B20-3ECB-44A8-AFC5-44B2F3126803

Q21198860-244CE0B4-BA0E-4F6F-89F7-4B1426616366

P2888

Q21198860-4AB3837D-1312-4553-B154-1D1C2514BDA7

P304

Q21198860-8E05BD44-02DB-4512-A7C6-8D3369712160

P31

Q21198860-05A1DDBD-0FED-4187-B3DA-1DBCE64EAC45

Q21198860-11FC705A-E4D7-4552-AA68-6DA14B83A6F9

P3181

Q21198860-95ACB155-31A5-4154-9F22-8745AD3126EA

P356

Q21198860-2435FCED-816E-4E24-9F5D-49A6AEE10C68

P407

Q21198860-6AAF1A42-A380-4867-8E64-74E6729781E3

P433

Q21198860-7C57C42A-096A-4312-9480-D5AE78A2E80B

P478

Q21198860-A043FCCC-213D-4B83-A770-E7A78DF582F0

P5008

Q21198860-8C28DBA9-F589-4EB4-8CEF-BBC94E875841

P577

Q21198860-BD29483C-BC8A-408E-ADCC-8DC7BE58CBDC

P5875

Q21198860-9BF502F6-FC1E-41D8-9731-A92A95C4A30F

P6179

Q21198860-15273CB1-E90D-4F88-A9EE-4E9CB1DAA7EB

P698

Q21198860-7EA68D85-93AB-43FC-BFA4-1B0833A92773

P921

Q21198860-1CB875AF-2D7A-4E7A-9879-BCB71F13EEBA

Q21198860-1E56A28F-2C0A-4237-850D-4C4B64675CD9

Q21198860-58FE3140-0E5C-4300-B0F4-3F560E79E6DD

Q21198860-6B67CD49-898B-4D11-BCA7-A2B9A79007AE

Q21198860-964DB35E-D7EF-4CD9-8133-D5D9E857B5F4

Q21198860-BADE8FC9-0D59-4885-9DDC-A2A83FCE5C69

Q21198860-E5645786-8506-40FE-B802-82124E888BEE

P932

Q21198860-C7ADF879-B22C-47AF-93B9-BAFDC80A3276

P3181

P356

P1433

Journal of Hematology & Oncology

P1476

B-Raf and the inhibitors: from bench to bedside

@en

P2093

Delong Liu

http://www.w3.org/2001/XMLSchema#string

Jian Zhuge

http://www.w3.org/2001/XMLSchema#string

Michael Karsy

http://www.w3.org/2001/XMLSchema#string

Minghao Zhong

http://www.w3.org/2001/XMLSchema#string

Tiangui Huang

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.0 Generic

P2860

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

Back to the roots: the remarkable RAF oncogene story

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

BRAF mutations in hairy-cell leukemia

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma

Mutations of the BRAF gene in human cancer

Primary structure of v-raf: relatedness to the src family of oncogenes

P2888

P304

30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1283680

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1756-8722-6-30

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2013-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236337146

http://www.w3.org/2001/XMLSchema#string

P6179

1020270887

http://www.w3.org/2001/XMLSchema#string

P698

23617957

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

proto-oncogene proteins

neoplasm proteins

P932

3646677

http://www.w3.org/2001/XMLSchema#string